TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21421174

Group type: EXPERIMENTAL
Intervention: Teacher-based preventive intervention implemented 3 months before the traumatic exposure.
Number of subjects: 1488

Group type: COMPARATOR
Intervention: Nonintervention control group exposed to the same traumatic events.
Number of subjects: 1488
Study: 19590194

Group type: COMPARATOR
Intervention: Amitriptyline 37.5 mg twice daily for 14 days (pilot study)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Amitriptyline 25 mg once daily for 28 days (phase II study)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Amitriptyline 50 mg once daily for 28 days (phase II study)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Amitriptyline 75 mg once daily for 28 days (phase II study)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 16520399

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 20
Study: 15253827

Group type: EXPERIMENTAL
Intervention: 11 mL of cold anesthetic gel (group 1)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Plain lubricating gel (group 2)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No gel (group 3)
Number of subjects: 33
Study: 10689265

Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (TDI)
Number of subjects: 20
Study: 9243105

Group type: EXPERIMENTAL
Intervention: Fasting immunoreactive insulin
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Total immunoreactive proinsulin
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Proinsulin/specific insulin ratio
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Specific insulin
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Proinsulin and proinsulin/specific insulin ratio
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: High proinsulin/specific insulin ratio
Number of subjects: 170
Study: 8440766

Group type: EXPERIMENTAL
Intervention: 7 mg nicotine per day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 14 mg nicotine per day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 21 mg nicotine per day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nicotine Transdermal System 21 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Combined administration of Nicotine Transdermal System 7 mg/day plus 14 mg/day
Number of subjects: 24
Study: 29584456

Group type: EXPERIMENTAL
Intervention: Avelumab alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avelumab in combination with pegylated liposomal doxorubicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin alone
Number of subjects: 0
Study: 28857740

Group type: EXPERIMENTAL
Intervention: Double-blind drug reduction programme leading to full withdrawal within 6 months.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Treatment as usual (control group maintained baseline level of medication).
Number of subjects: 22
Study: 26616122

Group type: EXPERIMENTAL
Intervention: Disclosure intervention plus usual care
Number of subjects: 298

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 298
Study: 23017512

Group type: EXPERIMENTAL
Intervention: Complete bladder neck preservation
Number of subjects: 208

Group type: COMPARATOR
Intervention: No preservation (control)
Number of subjects: 208
Study: 21352671

Group type: EXPERIMENTAL
Intervention: New chest physiotherapy method (CPT) with 31 sessions of nebulization of hypertonic saline followed by CPT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nebulization of hypertonic saline (27 sessions)
Number of subjects: 20
Study: 19011554

Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte transplantation on a 3-dimensional matrix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional ACI methods
Number of subjects: 0
Study: 16157462

Group type: EXPERIMENTAL
Intervention: Smokers in precontemplation stage
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Preparers
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Patients preparing to quit
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Smokers contemplating quitting and preparing to quit
Number of subjects: 633

Group type: COMPARATOR
Intervention: Unmotivated smokers
Number of subjects: 633

Group type: COMPARATOR
Intervention: Smokers motivated to quit
Number of subjects: 633
Study: 14632625

Group type: EXPERIMENTAL
Intervention: Predictable pain (100% probability)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Unpredictable pain (50% probability)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Comparison between predictable and unpredictable conditions
Number of subjects: 16
Study: 11071974

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - Oral conjugated oestrogen (0.625 mg) + medroxyprogesterone acetate (2.5 mg) daily for 12 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 65
Study: 9068933

Group type: EXPERIMENTAL
Intervention: Sertraline 200 mg/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 25
Study: 8450327

Group type: EXPERIMENTAL
Intervention: High-dose intravenous nicardipine
Number of subjects: 906

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 906
Study: 3785647

Group type: EXPERIMENTAL
Intervention: Phenytoin 100 mg
Number of subjects: 0
Study: 29720244

Group type: EXPERIMENTAL
Intervention: Taurolidine-citrate lock solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin alone (placebo)
Number of subjects: 0
Study: 26463420

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Therapy (MAD)
Number of subjects: 40
Study: 25257877

Group type: EXPERIMENTAL
Intervention: OCC (occlusion)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: RI (ramp incremental exercise)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: SVR (severe-intensity exercise)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: MOD (moderate-intensity exercise)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: VLP (vastus lateralis proximal)
Number of subjects: 7
Study: 23158856

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 100 mg intravenous, 3 times/day for 7 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 26
Study: 20627914

Group type: EXPERIMENTAL
Intervention: Bronchodilators (salbutamol plus ipratropium)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19097963

Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg/kg
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Meperidine 0.4 mg/kg
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 132
Study: 16177972

Group type: EXPERIMENTAL
Intervention: Echinilin (Echinacea purpurea) administered at onset of cold for 7 days, 5 mL/dose on day 1 and 3 doses on subsequent days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered at onset of cold for 7 days
Number of subjects: 0
Study: 12952843

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (10 mg/d) and ARB (candesartan, 8 mg/d) for 3 days (GTN+ARB group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Transdermal nitroglycerin (10 mg/d) for 3 days (GTN group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo skin patches and placebo tablets for 3 days (control group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Transdermal nitroglycerin (10 mg/d) (GTN group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (10 mg/d) and ARB (candesartan, 8 mg/d) (GTN+ARB group)
Number of subjects: 64
Study: 9892314

Group type: EXPERIMENTAL
Intervention: 30 g/day of glycine (N=9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Clozapine without glycine (N=10)
Number of subjects: 19
Study: 10829989

Group type: EXPERIMENTAL
Intervention: Children with severe malnutrition (grades III and IV PEM)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Children with marked linear growth retardation (height-for-age < 85% of normal)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Malnourished children with hypoalbuminemia (serum albumin < 2.5 g/dl)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Malnourished children with anemia (hemoglobin < or = 8.0 g/dl)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (12 children without PEM)
Number of subjects: 58
Study: 1866346

Group type: EXPERIMENTAL
Intervention: Denis‐Browne splint
Number of subjects: 0
Study: 6625248

Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg . kg‐1 and fentanyl 6 micrograms . kg‐1 (Group M)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Thiopentone 6 mg . kg‐1 and fentanyl 5 micrograms . kg‐1 (Group T)
Number of subjects: 19
Study: 30323006

Group type: EXPERIMENTAL
Intervention: Very Low Disease Activity (VLDA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease Activity Index for PsA (DAPSA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical (c-) DAPSA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDA 5/7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDA skin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDA joint
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDA joint + skin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DAPSA LDA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cDAPSA LDA
Number of subjects: 0
Study: 29041916

Group type: EXPERIMENTAL
Intervention: Coordinated rehabilitation programme with early onset of patient participation and intensified occupational therapy and physiotherapy after hip fracture surgery.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard care (Control Group).
Number of subjects: 126
Study: 26666500

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 50 mg/day
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 150 mg/day
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 5 mg/day
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (N01187)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (N01236)
Number of subjects: 106
Study: 24183608

Group type: EXPERIMENTAL
Intervention: €5 cash incentive
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Entry into a prize draw
Number of subjects: 1650

Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 1650
Study: 23766611

Group type: EXPERIMENTAL
Intervention: Intralesional Steroids
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Topical Steroids
Number of subjects: 30
Study: 20446083

Group type: EXPERIMENTAL
Intervention: VEN/ODV AUC metabolic ratio
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: ODV/VEN AUC metabolic ratio
Number of subjects: 141
Study: 17220728

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.05 mmol/kg)
Number of subjects: 60
Study: 15751604

Group type: EXPERIMENTAL
Intervention: Patients with APS1
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (11 sex‐ and age‐matched healthy subjects)
Number of subjects: 11
Study: 12081605

Group type: EXPERIMENTAL
Intervention: Thymosin-alpha1 and famciclovir combination therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Famciclovir monotherapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 32
Study: 10365354

Group type: EXPERIMENTAL
Intervention: GORD infants
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GORD infants (videofluoroscopy)
Number of subjects: 20
Study: 7491382

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 2024560

Group type: EXPERIMENTAL
Intervention: Droperidol (0.03 mg.kg‐1 to 0.25 mg.kg‐1) with fentanyl
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane and fentanyl
Number of subjects: 30
Study: 7042799

Group type: EXPERIMENTAL
Intervention: Polymerized ragweed (PRW)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 21
Study: 30764731

Group type: EXPERIMENTAL
Intervention: Angiography-based machine learning (ML) algorithm
Number of subjects: 1501
Study: 27046461

Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.25% + tramadol 1 mg/kg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.25% + tramadol 2 mg/kg
Number of subjects: 65

Group type: COMPARATOR
Intervention: levobupivacaine 0.25% (Control)
Number of subjects: 65
Study: 26435060

Group type: EXPERIMENTAL
Intervention: Glucose consumption (25% of daily energy requirements)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Fructose consumption (25% of daily energy requirements)
Number of subjects: 113

Group type: COMPARATOR
Intervention: High fructose corn syrup (HFCS) consumption (25% of daily energy requirements)
Number of subjects: 113
Study: 23400741

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn) 600 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn)
Number of subjects: 12
Study: 21175273

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 13

Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 13
Study: 19762734

Group type: EXPERIMENTAL
Intervention: 1.0 mL/kg of 0.225% ropivacaine (low volume/high concentration, LVHC)
Number of subjects: 73
Study: 17556779

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (12-week home-based)
Number of subjects: 31
Study: 15551194

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLA) 5-20 mg/d
Number of subjects: 28

Group type: COMPARATOR
Intervention: Flupenthixol (FLU) 5-20 mg/d
Number of subjects: 28
Study: 10658681

Group type: EXPERIMENTAL
Intervention: IL-2 + G-CSF mobilization
Number of subjects: 43

Group type: COMPARATOR
Intervention: G-CSF mobilization alone (Control)
Number of subjects: 43
Study: 9281930

Group type: EXPERIMENTAL
Intervention: Directed verbal prompts and positive reinforcement during nine consecutive meals
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 24
Study: 1313459

Group type: EXPERIMENTAL
Intervention: Strontium chloride hexahydrate-containing dentifrice (SCH) with one abrasive system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Strontium chloride hexahydrate-containing dentifrice (SCH) with another abrasive system
Number of subjects: 40
Study: 3935466

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (Nitroderm TTS 5)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31368191

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 5% dextrose (D5W)
Number of subjects: 52
Study: 29117472

Group type: EXPERIMENTAL
Intervention: Text messaging intervention (weekly messages for 22 weeks) in addition to healthy lifestyle counselling
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (counselling on healthy diet and exercise)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 26452978

Group type: EXPERIMENTAL
Intervention: Simplified papilla preservation flap (SPPF) with guided tissue regeneration (GTR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Simplified papilla preservation flap (SPPF) without guided tissue regeneration (GTR)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 18
Study: 25220877

Group type: EXPERIMENTAL
Intervention: Fast blood sampling (40 seconds)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Slow blood sampling (70 seconds)
Number of subjects: 20
Study: 22760109

Group type: EXPERIMENTAL
Intervention: SWEET (bilevel cycle ergometry endurance exercise training)
Number of subjects: 24

Group type: COMPARATOR
Intervention: OxCar (walking while pushing an OxCar and traditional diaphragmatic breathing)
Number of subjects: 24
Study: 21046932

Group type: EXPERIMENTAL
Intervention: 16 mg of OROS hydromorphone once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: 4 mg of immediate-release hydromorphone four times daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study: 18561878

Group type: EXPERIMENTAL
Intervention: Prophylactic Implantable Cardioverter Defibrillator (ICD) therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study: 16525182

Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy, intensity-modulated radiotherapy, brachytherapy, radiosurgery, photodynamic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Convection-enhanced delivery of chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New experimental therapies such as immunotherapy
Number of subjects: 0
Study: 12411282

Group type: EXPERIMENTAL
Intervention: Inhalation of 0.12, 0.9, or 7% saline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pretreatment with amiloride followed by inhalation of 0.12 and 0.9% saline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pretreatment with amiloride and inhalation of 7% saline
Number of subjects: 16

Group type: COMPARATOR
Intervention: Inhalation of vehicle (0.12% saline)
Number of subjects: 16
Study: 11074391

Group type: EXPERIMENTAL
Intervention: Screening and foot protection programme
Number of subjects: 69

Group type: COMPARATOR
Intervention: Special footwear
Number of subjects: 69

Group type: COMPARATOR
Intervention: Educational programmes
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Podiatric care
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Total contact casting
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Topical growth factors (particularly platelet-derived growth factor)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Topical ketanserin
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Systemic hyperbaric oxygen therapy
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Iloprost and prostaglandin E1 (PGE1)
Number of subjects: 69
Study: 8975251

Group type: EXPERIMENTAL
Intervention: newly developed film‐coated tablet with sustained release
Number of subjects: 24

Group type: COMPARATOR
Intervention: reference formulation
Number of subjects: 24
Study: 1310572

Group type: EXPERIMENTAL
Intervention: Foscarnet induction therapy at a dosage of 60 mg/kg 3 times/day via 1-hour intravenous infusion for 21 days.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foscarnet maintenance therapy at a dosage of 90 mg/kg/day via 2-hour infusion.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Foscarnet treatment delayed until the first signs of retinitis progression (Control group).
Number of subjects: 0
Study: 7398735

Group type: EXPERIMENTAL
Intervention: Microencapsulated digoxin capsules (0.38 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Commercial tablets (ultrarapidly dissolving)
Number of subjects: 8
Study: 31444589

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg enfortumab vedotin (Arm A)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 1.25 mg/kg enfortumab vedotin (Arm B)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both doses of enfortumab vedotin
Number of subjects: 17
Study: 31464638

Group type: EXPERIMENTAL
Intervention: STan (cardiotocographic electronic fetal monitoring plus ST segment analysis)
Number of subjects: 1818

Group type: COMPARATOR
Intervention: CTG alone (cardiotocography monitoring)
Number of subjects: 1818
Study: 29182706

Group type: EXPERIMENTAL
Intervention: 150mg BID tramiprosate
Number of subjects: 147
Study: 25630874

Group type: EXPERIMENTAL
Intervention: Allogeneic HCT
Number of subjects: 26
Study: 25011237

Group type: EXPERIMENTAL
Intervention: Men with schizophrenia
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Men with localized frontal lobe lesions
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy men (control group)
Number of subjects: 90
Study: 21857489

Group type: EXPERIMENTAL
Intervention: Viral suppression group (initiated ART)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Drug conservation group (deferred ART)
Number of subjects: 254
Study: 19689568

Group type: EXPERIMENTAL
Intervention: Incredible Years Teacher Training Programme supplemented by a curriculum unit on social and emotional skills
Number of subjects: 15
Study: 18254574

Group type: EXPERIMENTAL
Intervention: Prednisolone oral solution + placebo tablets + procaterol MDI
Number of subjects: 43

Group type: COMPARATOR
Intervention: Prednisolone tablets + placebo oral solution + procaterol MDI
Number of subjects: 43
Study: 16311201

Group type: EXPERIMENTAL
Intervention: Partial weight bearing (200 N)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Elderly patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Force time integrals (impulses transferred to the ground)
Number of subjects: 34
Study: 14568892

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.3 mg)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 10736933

Group type: EXPERIMENTAL
Intervention: sulphurous‐arsenical‐ferruginous water (group A)
Number of subjects: 37

Group type: COMPARATOR
Intervention: drinking water from the city mains (group B)
Number of subjects: 37
Study: 8833634

Group type: EXPERIMENTAL
Intervention: Group 1 (patients set their own priorities)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group 2 (DSN set educational priorities)
Number of subjects: 40
Study: 2097565

Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg b.i.d. e.v.) starting from the day before the operation and continuing for the following seven days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Calcium heparin (5,000 IU b.i.d. by s.c. route) from day 0 to the 7th post-operative day
Number of subjects: 100
Study: 6252780

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 33